These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 34500130)

  • 1. Cysteine derivatives as acetyl lysine mimics to inhibit zinc-dependent histone deacetylases for treating cancer.
    Wang J; Cao Z; Wang F; Wang P; An J; Fu X; Liu T; Li Y; Li Y; Zhao Y; Lin H; He B
    Eur J Med Chem; 2021 Dec; 225():113799. PubMed ID: 34500130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
    Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
    Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
    Cheng C; Yun F; He J; Ullah S; Yuan Q
    Eur J Med Chem; 2019 Jul; 173():185-202. PubMed ID: 31003060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and antitumor activity evaluation of novel HDAC inhibitors with tetrahydrobenzothiazole as the skeleton.
    Sun S; Zhao W; Li Y; Chi Z; Fang X; Wang Q; Han Z; Luan Y
    Bioorg Chem; 2021 Mar; 108():104652. PubMed ID: 33497873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilization of cyanopyridine in design and synthesis of first-in-class anticancer dual acting PIM-1 kinase/HDAC inhibitors.
    Bass AKA; Nageeb EM; El-Zoghbi MS; Mohamed MFA; Badr M; Abuo-Rahma GEA
    Bioorg Chem; 2022 Feb; 119():105564. PubMed ID: 34959179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological study of class I selective HDAC inhibitors with NO releasing activity.
    Ding Q; Liu C; Zhao C; Dong H; Xu Q; James Chou C; Zhang Y
    Bioorg Chem; 2020 Nov; 104():104235. PubMed ID: 32896808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New benzothiazole/thiazole-containing hydroxamic acids as potent histone deacetylase inhibitors and antitumor agents.
    Tung TT; Oanh DT; Dung PT; Hue VT; Park SH; Han BW; Kim Y; Hong JT; Han SB; Nam NH
    Med Chem; 2013 Dec; 9(8):1051-7. PubMed ID: 23521008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
    Wang B; Chen X; Gao J; Su L; Zhang L; Xu H; Luan Y
    Bioorg Med Chem Lett; 2019 Sep; 29(18):2638-2645. PubMed ID: 31400938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purine/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors.
    Nepali K; Chang TY; Lai MJ; Hsu KC; Yen Y; Lin TE; Lee SB; Liou JP
    Eur J Med Chem; 2020 Jun; 196():112291. PubMed ID: 32325365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
    Chen Y; Wang X; Xiang W; He L; Tang M; Wang F; Wang T; Yang Z; Yi Y; Wang H; Niu T; Zheng L; Lei L; Li X; Song H; Chen L
    J Med Chem; 2016 Jun; 59(11):5488-504. PubMed ID: 27186676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of class I histone deacetylase inhibitors based on romidpesin with promising selectivity for cancer cells.
    Zhang K; Yao Y; Tu Z; Liao C; Wang Z; Qiu Y; Chen D; Hamilton DJ; Li Z; Jiang S
    Future Med Chem; 2020 Feb; 12(4):311-323. PubMed ID: 31782319
    [No Abstract]   [Full Text] [Related]  

  • 12. Synthesis and biological characterization of spiro[2H-(1,3)-benzoxazine-2,4'-piperidine] based histone deacetylase inhibitors.
    Thaler F; Varasi M; Abate A; Carenzi G; Colombo A; Bigogno C; Boggio R; Zuffo RD; Rapetti D; Resconi A; Regalia N; Vultaggio S; Dondio G; Gagliardi S; Minucci S; Mercurio C
    Eur J Med Chem; 2013 Jun; 64():273-84. PubMed ID: 23644210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
    Xie R; Li Y; Tang P; Yuan Q
    Eur J Med Chem; 2018 Jan; 143():320-333. PubMed ID: 29202397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel tubulin/HDAC dual-targeting inhibitors with strong antitumor and antiangiogenic potency.
    Wang Y; Sun M; Wang Y; Qin J; Zhang Y; Pang Y; Yao Y; Yang H; Duan Y
    Eur J Med Chem; 2021 Dec; 225():113790. PubMed ID: 34454126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and anticancer activity of novel valproic acid conjugates with improved histone deacetylase (HDAC) inhibitory activity.
    Ibrahim TS; Sheha TA; Abo-Dya NE; AlAwadh MA; Alhakamy NA; Abdel-Samii ZK; Panda SS; Abuo-Rahma GEA; Mohamed MFA
    Bioorg Chem; 2020 Jun; 99():103797. PubMed ID: 32247939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
    Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M
    Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lactam-based HDAC inhibitors for anticancer chemotherapy: restoration of RUNX3 by posttranslational modification and epigenetic control.
    Cho M; Choi E; Kim JH; Kim H; Kim HM; Lee JI; Hwang KC; Kim HJ; Han G
    ChemMedChem; 2014 Mar; 9(3):649-56. PubMed ID: 24376239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naturally occurring benzoic acid derivatives retard cancer cell growth by inhibiting histone deacetylases (HDAC).
    Anantharaju PG; Reddy BD; Padukudru MA; Kumari Chitturi CM; Vimalambike MG; Madhunapantula SV
    Cancer Biol Ther; 2017 Jul; 18(7):492-504. PubMed ID: 28506198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
    Cincinelli R; Musso L; Giannini G; Zuco V; De Cesare M; Zunino F; Dallavalle S
    Eur J Med Chem; 2014 May; 79():251-9. PubMed ID: 24742384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
    Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
    Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.